UNITED STATES OF AMERICA Before the SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Administrative Proceedings Rulings Release No. 5872 / June 27, 2018

Administrative Proceeding File No. 3-18141

In the Matter of

CellCyte Genetics Corp., China Pediatric Pharmaceuticals, Inc., and Hawker Energy, Inc.

Notice of Stay

On August 28, 2017, the Securities and Exchange Commission issued an order instituting proceedings pursuant to Section 12(j) of the Securities Exchange Act of 1934, alleging that Respondents have securities registered with the Commission under Section 12(g) of the Exchange Act and are delinquent in their periodic filings. The only remaining respondent is China Pediatric Pharmaceuticals, Inc., which has not yet been served with the OIP.¹

This is notice that on June 21, 2018, the Commission stayed effective immediately all matters pending before administrative law judges in light of the Supreme Court's decision in *Lucia v. SEC*, No. 17-130 (U.S. June 21, 2018). *Pending Admin. Proc.*, Securities Act Release No. 10510, 2018 SEC LEXIS 1490 (June 21, 2018). The stay will last until July 23, 2018, or further order of the Commission. *Id*.

Brenda P. Murray Chief Administrative Law Judge

¹ CellCyte Genetics Corp., Exchange Act Release No. 81621, 2017 SEC LEXIS 2865 (Sept. 14, 2017); CellCyte Genetics Corp., Initial Decision Release No. 1184, 2017 SEC LEXIS 3237 (ALJ Oct. 10, 2017).